Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Holdings Lifted by US Bancorp DE

US Bancorp DE raised its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLAGet Rating) by 38.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,040 shares of the company’s stock after buying an additional 3,345 shares during the period. US Bancorp DE’s holdings in Intellia Therapeutics were worth $673,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Wipfli Financial Advisors LLC bought a new position in shares of Intellia Therapeutics in the third quarter valued at $25,000. National Bank of Canada FI acquired a new stake in Intellia Therapeutics during the 3rd quarter valued at $39,000. China Universal Asset Management Co. Ltd. raised its stake in Intellia Therapeutics by 462.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 866 shares of the company’s stock valued at $48,000 after purchasing an additional 712 shares during the period. Penserra Capital Management LLC acquired a new stake in Intellia Therapeutics during the 1st quarter valued at $97,000. Finally, High Net Worth Advisory Group LLC raised its stake in Intellia Therapeutics by 33.3% during the 3rd quarter. High Net Worth Advisory Group LLC now owns 2,000 shares of the company’s stock valued at $112,000 after purchasing an additional 500 shares during the period. Institutional investors own 85.61% of the company’s stock.

Analyst Upgrades and Downgrades

NTLA has been the topic of several recent analyst reports. EF Hutton Acquisition Co. I initiated coverage on shares of Intellia Therapeutics in a research note on Tuesday, November 1st. They set a “buy” rating and a $130.00 target price on the stock. Raymond James reduced their price objective on Intellia Therapeutics from $127.00 to $124.00 and set an “outperform” rating for the company in a research report on Friday, November 4th. Chardan Capital lifted their price objective on Intellia Therapeutics from $121.00 to $129.00 and gave the company a “buy” rating in a research report on Monday, November 14th. Wells Fargo & Company reduced their price target on Intellia Therapeutics from $135.00 to $120.00 and set an “overweight” rating for the company in a report on Wednesday, January 4th. Finally, JMP Securities lowered Intellia Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday. Two analysts have rated the stock with a sell rating, two have issued a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $102.72.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $33.85 on Friday. The company’s fifty day moving average is $40.61 and its two-hundred day moving average is $52.80. Intellia Therapeutics, Inc. has a 52-week low of $32.44 and a 52-week high of $104.87. The firm has a market capitalization of $2.66 billion, a price-to-earnings ratio of -5.77 and a beta of 1.93.

Intellia Therapeutics (NASDAQ:NTLAGet Rating) last posted its quarterly earnings results on Thursday, November 3rd. The company reported ($1.49) EPS for the quarter, missing the consensus estimate of ($1.31) by ($0.18). Intellia Therapeutics had a negative net margin of 859.92% and a negative return on equity of 47.79%. The firm had revenue of $13.27 million during the quarter, compared to analyst estimates of $13.60 million. As a group, sell-side analysts expect that Intellia Therapeutics, Inc. will post -6.02 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO John M. Leonard sold 6,673 shares of the stock in a transaction on Wednesday, January 4th. The shares were sold at an average price of $37.21, for a total value of $248,302.33. Following the completion of the transaction, the chief executive officer now owns 766,825 shares in the company, valued at approximately $28,533,558.25. The sale was disclosed in a filing with the SEC, which is available at this link. In other news, CEO John M. Leonard sold 6,673 shares of the company’s stock in a transaction that occurred on Wednesday, January 4th. The stock was sold at an average price of $37.21, for a total value of $248,302.33. Following the sale, the chief executive officer now directly owns 766,825 shares in the company, valued at approximately $28,533,558.25. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Glenn Goddard sold 2,427 shares of the stock in a transaction on Wednesday, January 4th. The stock was sold at an average price of $37.21, for a total value of $90,308.67. Following the transaction, the chief financial officer now owns 15,404 shares of the company’s stock, valued at $573,182.84. The disclosure for this sale can be found here. Insiders sold a total of 11,608 shares of company stock valued at $431,934 over the last ninety days. 2.60% of the stock is owned by company insiders.

Intellia Therapeutics Profile

(Get Rating)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.

Featured Stories

Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.